Pharvaris N.V.

Contributing Author

Recent Articles by Pharvaris N.V.

Oct-23	Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting PHVS GlobeNewswire
Aug-12	Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update PHVS GlobeNewswire
Jul-24	Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares PHVS GlobeNewswire
Jul-22	Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants PHVS GlobeNewswire
Jul-22	Pharvaris Announces Proposed Public Offering of Ordinary Shares PHVS GlobeNewswire
Jul-10	Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025 PHVS GlobeNewswire
Jun-27	Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit PHVS GlobeNewswire
Jun-16	Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress PHVS GlobeNewswire
Jun-10	Pharvaris Announces Annual Meeting of Shareholders PHVS GlobeNewswire
Jun-02	Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema PHVS GlobeNewswire
May-19	Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses PHVS GlobeNewswire
May-13	Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update PHVS GlobeNewswire
May-12	Pharvaris to Host a Virtual R&D Call "Deucrictibant: Beyond HAE Type 1/2" on June 4 PHVS GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.